Sintilimab

Generic Name: Sintilimab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2072873-06-2

Unique Ingredient Identifier: 8FU7FQ8UPK

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC

Phase 2

Conditions: Colorectal Neoplasms

Interventions: Radiation: hypofractionation Radiotherapy
Drug: sintilimab
Drug: GM-CSF
Drug: Fruquintinib

First Posted Date: 2022-03-23

Last Posted Date: 2022-03-31

Lead Sponsor: The First Affiliated Hospital of Xiamen University

Target Recruit Count: 71

Registration Number: NCT05292417

Locations: 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

Phase 2

Not yet recruiting

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: Sintilimab
Drug: Rituximab

First Posted Date: 2022-03-15

Last Posted Date: 2022-03-15

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 100

Registration Number: NCT05280626

Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma

Phase 2

Recruiting

Conditions: Intrahepatic Cholangiocarcinoma

Interventions: Drug: Sintilimab
Drug: IBI305
Drug: GEMOX

First Posted Date: 2022-02-23

Last Posted Date: 2022-02-23

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 90

Registration Number: NCT05251662

Locations: 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China

TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Procedure: TACE/HAIC
Procedure: liver resection
Drug: Lenvatinib
Drug: Sintilimab

First Posted Date: 2022-02-22

Last Posted Date: 2023-10-13

Lead Sponsor: Third Affiliated Hospital, Sun Yat-Sen University

Target Recruit Count: 90

Registration Number: NCT05250843

Locations: 🇨🇳
Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China

Sintilimab Plus NCT or NCRT Versus NCRT for ESCC

Phase 3

Not yet recruiting

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: Sintilimab
Drug: Chemotherapy
Radiation: radiotherapy

First Posted Date: 2022-02-17

Last Posted Date: 2022-10-25

Lead Sponsor: Sichuan Cancer Hospital and Research Institute

Target Recruit Count: 420

Registration Number: NCT05244798

Locations: 🇨🇳
Sichuan Cancer Hospital and Research Institute, Chengdu, Sichuan, China

PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer

Phase 3

Recruiting

Conditions: Colorectal Carcinoma

Interventions: Drug: Sintilimab
Drug: Oxaliplatin
Drug: capecitabine

First Posted Date: 2022-02-11

Last Posted Date: 2022-12-30

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 323

Registration Number: NCT05236972

Locations: 🇨🇳
Sun Yat-sen University, Guangzhou, China

Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT

Phase 1

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Sintilimab
Drug: Lenvatinib
Radiation: radiotherapy

First Posted Date: 2022-02-04

Last Posted Date: 2023-02-08

Lead Sponsor: Beijing Tsinghua Chang Gung Hospital

Target Recruit Count: 20

Registration Number: NCT05225116

Locations: 🇨🇳
Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China

SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

Phase 2

Not yet recruiting

Conditions: Sintilimab
Gastric or Gastroesophageal Junction Adenocarcinoma
Locally Advanced Solid Tumor
S-1
HER2-positive
Immunotherapy
Oxaliplatin

Interventions: Drug: sintilimab
Drug: Trastuzumab
Drug: S-1 plus oxaliplatin

First Posted Date: 2022-02-01

Last Posted Date: 2022-04-06

Lead Sponsor: Aiping Zhou

Target Recruit Count: 44

Registration Number: NCT05218148

Locations: 🇨🇳
Cancer Hospital & Institute, Chinese Academy of Medical Sciences, Beijing, China

PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma.

Phase 2

Not yet recruiting

Conditions: Cholangiocarcinoma

Interventions: Drug: Sintilimab

First Posted Date: 2022-01-26

Last Posted Date: 2022-01-26

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 73

Registration Number: NCT05207735

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

Phase 2

Recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Sintilimab
Drug: Capecitabine

First Posted Date: 2022-01-21

Last Posted Date: 2022-05-06

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 150

Registration Number: NCT05201859

Locations: 🇨🇳
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy